Investigating Predictors of Outcomes From LENS

NCT ID: NCT07339917

Last Updated: 2026-01-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

4400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-04-30

Study Completion Date

2032-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Anxiety is a very common mental health problem. For people living with anxiety, it can have a huge impact on their lives. There are treatments that can help, such as Cognitive Behavioural Therapy (CBT). However, about half of the people who receive treatment still struggle with anxiety after treatment is complete, and we do not yet know why. In this study, we hope to find factors that help explain why people respond differently to anxiety treatment. To answer this question, people in this study will receive a digital anxiety treatment called Learning Effective New Strategies (LENS). LENS is a type of brain training that helps people make less negative interpretations of uncertain situations and information. LENS has been proven to help reduce worry and anxiety, and improve mood (Hirsch et al., 2021). After participants finish LENS, we will measure how their patterns of thinking and mood changes over treatment and during the following five months. We will invite people to take part through multiple existing research studies (e.g. GLAD, TEDS) who have already shared their genetic data (information about their DNA). This way of recruiting would allow us to combine this genetic data with information from questionnaires to look for genetic and psychological factors that are linked with how well someone's anxiety improves after treatment. This research could help us understand what factors are linked to a person's outcomes from treatment. In the future, this could help health professionals personalise anxiety treatment and offer the right treatment to people sooner. This would mean that fewer people need to try multiple treatments before finding one that works. We hope this study will improve care for people living with anxiety.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anxiety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Learning Effective New Strategies (LENS)

Learning Effective New Strategies (LENS) is a Class I digital mental health intervention developed by King's College London, of which the overall purpose is to shift the way people think about ambiguous situations to be more positive and helpful. LENS achieves this through a drill-like training where users are prompted to visualise positive conclusions to numerous situations which are ambiguous and could be interpreted in either negative or positive ways. This training involves completing 12 sessions over 4 weeks. This type of training is known as cognitive bias modification for interpretation bias (CBM-I), which trains individuals to think in a more positive, adaptive way. The intended use of LENS is to reduce anxiety, depression and/or repetitive negative thinking in individuals with anxiety (low to high levels), depression (low to moderate levels), and/or repetitive negative thinking (moderate to high levels).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults over the age of 18
* Fluent in English
* Normal or corrected to normal hearing
* Normal or corrected to normal vision
* Currently experiencing anxiety (GAD-7 score ≥ 8)
* Access to stable internet connection
* Access to smartphone, laptop, computer, or tablet

Exclusion Criteria

* Current high levels of suicidal ideation, as defined by a score ≥ 2 on Item 9 of the PHQ-9 OR score of 1 on Item 9 of the PHQ-9 and score ≥21 on the SIDAS
* Suicide attempt in past two years.
* Current or history of psychosis or bipolar disorder.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

King's College London

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Colette R Hirsch

Role: PRINCIPAL_INVESTIGATOR

King's College London

Thalia Eley

Role: PRINCIPAL_INVESTIGATOR

King's College London

Gerome Breen

Role: PRINCIPAL_INVESTIGATOR

King's College London

Ewan Carr

Role: PRINCIPAL_INVESTIGATOR

King's College London

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Colette R Hirsch

Role: CONTACT

+44 (0) 20 7848 0697

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

363721

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.